miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer

Abstract Background Triple negative breast cancer (TNBC) lacks both early detection biomarkers and viable targeted therapeutics. Moreover, chemotherapy only produces 20–30% pathologic complete response. Because miRNAs are frequently dysregulated in breast cancer and have broad tissue effects, indivi...

Full description

Bibliographic Details
Main Authors: Hao-Yi Li, Jui-Lin Liang, Yao-Lung Kuo, Hao-Hsien Lee, Marcus J. Calkins, Hong-Tai Chang, Forn-Chia Lin, Yu-Chia Chen, Tai-I Hsu, Michael Hsiao, Luo-Ping Ger, Pei-Jung Lu
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Breast Cancer Research
Subjects:
miR-105
miR-93-3p
Biomarker
Cisplatin
Drug resistance
Triple negative breast cancer
Online Access:http://link.springer.com/article/10.1186/s13058-017-0918-2

Internet

http://link.springer.com/article/10.1186/s13058-017-0918-2

Similar Items